MRK stock's annual dividend yield of ~3.4% is appealing, but given the challenges ahead, it’s not a top 5 "buy" in Big Pharma currently. In 2025, the company is guiding for revenues of $64.1bn - ...

Large deals involving pharmaceutical and biotech companies are stalling as executives grapple with mercurial White House ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

We recently published a list of Top 10 Stocks to Buy According to XN Exponent Advisors LLC. In this article, we are going to ...

One poster demonstrating cell-free DNA molecular response as a potential surrogate endpoint to measure clinical efficacy of azenosertib in ...

POOR PIERRE — Mere months ago, the Conservative Party in Canada looked headed towards a landslide victory. Its leader, Pierre Poilievre, was ascendant and drawing rave reviews from much of the ...

Billionaire Ken Fisher, a prominent money manager, renowned author, and financial analyst, is the founder of Fisher Asset Management.

Bayer was ordered to pay more than $2 billion by a jury in a Georgia state court in the latest legal case surrounding alleged ...

Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...